News and Events - Cardionovum®

Latest press release

Nov 07, 2022

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >> Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Sep 09, 2022

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >> CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

Aug 02, 2022

Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

CARDIONOVUM® today announced the enrollment of the first patient in the International Hyper II Clinical Study

Learn more >> Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

June 08, 2022

CARDIONOVUM® announces the first Signature RCT patient enrollment

On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled

Learn more >> CARDIONOVUM® announces the first Signature RCT patient enrollment

Mar 31, 2021

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >> CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Jan 24, 2021

Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.

Marc Bosiers (St. Blasius Hospital, Dendermonde, Belgium) will give an update at LINC today on the results of the REFLOW1 study, which investigated the efficacy of the LEGFLOW® drug-coated balloon (DCB) in TASC C and D femoropopliteal lesions.

Learn more >> Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.